28 results about "Poly-L-lactide" patented technology

This disclosure relates to crystalline forms of 3-acyl-buprenorphine derivatives and sustained release injectable pharmaceutical compositions for treatment of opioid dependence, pain or depression, including an aqueous suspension of crystalline 3-acyl-buprenoprhine, or a pharmaceutically acceptable salt thereof, wherein the composition does not include an organic solvent, a polylactide polymer, a polyglycolide polymer, or a copolymer of polylactide and polyglycolide. This disclosure also includes 3-acyl-buprenoprhine or a pharmaceutically acceptable salt thereof prepared in a controlled release matrix, including poly(lactide-co-glycolide), sucrose acetoisobutyrate, lecithin, diolein and a combination of two or more thereof.

This invention relates to the field of lyophilized formulation technology, specifically disclosing an esupagglutide α-nano-lyophilized micelle and its preparation method. The micelles of this invention utilize polylactic-co-hydroxyacetic acid copolymer and sodium phosphatidylglycerol as micelle carriers, with arginine and cysteine ​​providing branching synergistic effects. Homogenization via film formation and low-temperature lyophilization yield lyophilized nano-micelle powder. The nano-micelle powder reduces protein oxidative decomposition during lyophilization, decreases impurity fragments, and reduces various non-fucose glycosylation, basic components (succinimide, methionine oxidation products), N-terminal deletion, Asn deamidation, and Met and Trp residue oxidation impurities that affect product quality. Product quality analysis and animal experiments after reconstitution show good resistance to impurities and degradation risk. The reconstituted esupagglutide α-nano-micelle system exhibits better stability and sustained-release properties, enhancing the hypoglycemic sustained-release effect 72 hours after injection, significantly improving upon conventional non-micelle formulations.

The application relates to an electrostatic spinning anti-adhesion membrane and a preparation method and application thereof. The electrostatic spinning anti-adhesion membrane comprises an inner layer, an intermediate layer and an outer layer which are sequentially stacked; the inner layer comprises polyglycolide-lactide-polyethylene glycol, the intermediate layer comprises polyglycolide-lactide, and the outer layer comprises polylactic acid-caprolactone. The electrostatic spinning anti-adhesion membrane has a three-dimensional nanofiber network structure of a biomimetic extracellular matrix, excellent mechanical properties, body temperature response softening and gradient degradation characteristics, can balance the degradation speed and the mechanical properties, reduce the mechanical damage of the material to the surrounding tissues, and can effectively prevent postoperative tissue adhesion.

The application discloses a preparation method of an anti-adhesion, repair-promoting and antibacterial composite patch. L-lactide and glycolide are used as monomers to synthesize four-arm polylactic acid-glycolic acid 4arm-PLGA through ring-opening polymerization; then, L-lysine and 1,2-propylene glycol are used to prepare hydrophilic BLPD through esterification reaction, and the 4arm-PLGA is copolymerized with the 4arm-PLGA to obtain a block copolymer 4arm-PLGA-BLPD; subsequently, the proportion of PCL, the 4arm-PLGA-BLPD, the 4arm-PLGA and an antibacterial drug is regulated, and the composite patch is prepared through continuous electrospinning technology. The composite patch has good biosafety, antibacterial property, anti-adhesion between the patch and human organs and repair-promoting property, and has a wide application prospect in surgical operations, especially in hernia repair.

The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).

Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle. Methods for making and using the implants to reduce ocular hypertension and intraocular pressure in a patient are described.

The invention discloses a method for preparing polylactic acid by separating and purifying L-lactide, which is characterized by comprising the following steps: (1) mixing oligomeric lactic acid and a catalyst, feeding the mixture into a depolymerization reaction system, separating out a stream 12, feeding the stream 12 into a suspension crystallization system, and feeding a stream 15 into a third rectifying tower for purification; (2) feeding a stream 13 purified by the suspension crystallization system into a polymerization unit, and feeding crystallization mother liquor into a first rectifying tower through a stream 17; a stream 19 purified by the first rectifying tower enters a third rectifying tower, and a stream 20 separated by the first rectifying tower enters a second rectifying tower; (3) feeding a stream 22 extracted from the top of the second rectifying tower into a suspension crystallization system, and returning a stream 23 separated from the second rectifying tower to the first rectifying tower; (4) feeding a stream 25 extracted from the third rectifying tower into an m-lactide collecting tank; and (5) extracting polylactic acid from the polymerization unit. The method is high in product yield, high in efficiency, high in byproduct utilization rate and capable of effectively reducing energy consumption.

In the existing polylactic acid production, lactide is firstly prepared from lactic acid or purchased, and then lactide is subjected to ring-opening polymerization by using a relatively expensive catalyst such as metal zinc elementary substance, so that polylactic acid is prepared in two steps. According to the scheme, food-grade zinc acetate dihydrate is used as a catalyst for catalyzing lactic acid to accelerate dehydration condensation reaction, and lactic acid obtained by fermenting lactic acid bacteria after saccharification of starch is subjected to one-step catalysis is heated, stirred and polycondensed at a proper temperature to prepare polylactic acid. The whole process is free of disordered interference reaction, and all reactant products belong to food grade, are non-toxic and harmless, and are ecological and environment-friendly. Complex and expensive instruments, equipment and reagents are not needed. Zinc acetate dihydrate is easily dissolved in a lactic acid aqueous solution, ionized zinc ions have two valence states of + 1 valence and + 2 valence, an empty electron orbital and a unique Ar 3d10 electronic structure and have strong electronegativity, the + 1 valence zinc ions lose or obtain one electron, the surfaces of the zinc ions have rich catalytic active sites, and the catalytic activity of the zinc ions is improved. In an acid environment of a lactic acid solution, zinc ions catalyze hydroxyl carboxyl contained in lactic acid molecules to accelerate transition loss of electrons with different probabilities and probabilities or shift deflection of direction, angle and the like of shared electrons, so that water molecules are formed and removed, and dehydration condensation of hydroxyl carboxyl in lactic acid molecules and between lactic acid molecules is continuously catalyzed; and carrying out polycondensation on the oligomeric lactic acid to obtain polylactic acid. Meanwhile, a small amount of intermediate lactide formed by heating and catalyzing is also subjected to ring-opening polymerization reaction to form a linear polylactic acid chain.

The invention belongs to the technical field of crossing of biological medicine and advanced manufacturing, and particularly relates to a 4D printing gastric retention preparation for drug sustained release. The 4D printing gastric retention preparation is prepared by performing 4D printing on a composite material containing a medicine and a shape memory polymer, the shape memory polymer is a blend of polylactic acid (PLA) and polyvinyl alcohol (PVA), and the proportion of the PLA to the PVA is configured to regulate and control the drug release behavior and the physical retention performance of the preparation in the stomach environment; the gastric retention preparation is provided with a first permanent shape and a second temporary shape, the first permanent shape can be obtained by triggering the second temporary shape at a triggering temperature, and the triggering temperature is 35-40 DEG C. The device can be triggered under the human body stomach temperature (37 DEG C) and body fluid environment, changes from a compact temporary shape to an expanded permanent shape, can be retained in the stomach for 8 hours and can be safely discharged after medicine release, and long-acting retention in the stomach and medicine controlled release are achieved.

The application discloses a method for preparing lactide by cracking polylactic acid with lithium amine imine catalyst, and belongs to the technical field of chemical recycling of polylactic acid. The method comprises the following steps: dissolving polylactic acid in a solvent, adding methanol and a lithium amine imine catalyst to perform a pre-depolymerization reaction; removing the solvent by evaporation, then increasing the temperature to perform depolymerization, and recovering lactide monomers under reduced pressure. The method generates oligomers by pre-depolymerization to serve as endogenous reaction media, thereby reducing the depolymerization temperature and improving the depolymerization efficiency. The method has the advantages of small catalyst dosage, no heavy metal residue, simple post-treatment, high lactide yield, good selectivity and the like, and can be used for high-value recycling of polylactic acid waste and substandard products.

The invention discloses an SIS-loaded polymer tubular structure artificial blood vessel, and relates to the technical field of biomedical treatment, and the SIS-loaded polymer tubular structure artificial blood vessel comprises a polymer tubular structure which is prepared from a high polymer material through an electrostatic spinning or 3D printing process, the high polymer material is selected from at least one of polycaprolactone, polylactic acid, polyurethane, a polylactic acid-glycolic acid copolymer, poly (L-lactide-caprolactone) or poly (p-dioxanone); and the SIS layer is prepared by dissolving SIS powder in 0.1-1M acetic acid solution to prepare a 1%-10% solution. The invention relates to a preparation method of an SIS-loaded polymer tubular structure artificial blood vessel. The preparation method comprises the following steps: preparing SIS: cleaning and segmenting fresh small intestine and jejunum, and scraping an outer membrane, a muscular layer and an inner mucosa; according to the invention, a physical perfusion-freeze drying method is innovatively adopted to realize efficient loading of SIS; and more than 95% of active factors in the SIS are reserved through a gradient decellularization process.

The invention relates to the field of biomedical materials, in particular to cyanoacrylate medical blood vessel blocking glue and a preparation method thereof.The cyanoacrylate medical blood vessel blocking glue is prepared from, by mass, 30-35 parts of 2-octyl cyanoacrylate, 7-8 parts of lactide modified hydroxyethyl methylacrylate, 0.02-0.03 part of polymerization inhibitor propyl gallate, 0.02-0.03 part of initiator, 0.02-0.03 part of initiator, 0.02-0.03 part of initiator, 0.02-0.03 part of initiator and the balance water. By innovatively adopting various functional components and carrying out synergistic compatibility and precise preparation, compared with the prior art, the comprehensive performance of the product is remarkably improved, and the plugging agent has the advantages of rapid and reliable plugging effect, good plugging effect, good plugging effect, good plugging effect, good plugging effect, good plugging effect, good plugging effect, good plugging effect, good plugging effect and the like. Meanwhile, good biocompatibility, intraoperative developing capacity and a potential drug sustained release function are achieved, operation is easy and convenient, performance is stable, a safer and more efficient choice is provided for clinical vascular interventional therapy, and wide application prospects are achieved in the fields of cardiovascular and neurological intervention, peripheral vascular embolism and the like.

This application discloses a sustained-release formulation composition of lumateperone, comprising lumateperone or a salt thereof and a polymer material. The mass ratio of lumateperone to the polymer material is 0.5:9.5 to 5:5, and the polymer material comprises a main material, polylactide, and a selectively present release modifier, the mass of which is 0% to 95% of the main material, polylactide, and the release modifier is a mixture of one or more selected from polylactide or poly(lactide-co-glycolide). The sustained-release formulation of the present invention can achieve a sustained-release effect from one week to three months, can improve patient compliance, and does not have a clear burst release in the early stages, does not have a release delay period, the release of the formulation is stable, and the safety and efficacy of drug release are ensured.

This invention relates to a lactide composition comprising: lactide and an anti-hydrolysis aid, wherein the anti-hydrolysis aid comprises a molecular sieve and / or an inorganic filler, the molecular sieve having a pore size of 0.1 to 1 nm and the inorganic filler having a particle size of 800 to 3000 mesh; wherein, based on the weight of lactide: the amount of the molecular sieve is 0.01 to 5% by weight; and / or the amount of the inorganic filler is 0.01 to 5% by weight.

Provided herein are compositions comprising a bone composite and methods for treating bone defects, along with heating systems for processing the composite. The bone composite comprises about 35-50 wt.% bone component, about 10-30 wt.% polyethylene glycol, and about 30-40 wt.% PLGA (poly(dl-lactide-co-glycolide)) with a lactide-to-glycolide ratio between about 75:25 and about 85: 15, becoming moldable upon heating to between about the glass transition temperature and about the melting point (70-130 °C) of the polymer and setting into a rigid, resorbable implant upon cooling. Embodiments include variations in formulation and viscosity- and melt-controlling means. The disclosed heater provides a target heat load using direct contact, integrated, dual-chamber, or chemical heat source designs and is configured as a single-use device to maintain sterility. Intraoperative kits incorporating the composite, heater, and usage instructions are also described.

The invention relates to the technical field of medicine, and discloses a preparation method of a PLGA biodegradable sustained-release preparation of a cyclocytidine hydrochloride medicine, the preparation method comprises the following steps: organic phase preparation, primary emulsion preparation, multiple emulsion preparation, solvent volatilization and post-treatment, the molar ratio of lactide to glycolide of a polylactic acid-glycolic acid copolymer is 75: 25, and the molar ratio of lactide to glycolide of a cyclocytidine hydrochloride medicine is 1: 1. The concentration of the cyclic cytidine hydrochloride aqueous solution is 28%. Through slow drug release treatment of the spherical powder on the tumor part, the drug concentration of the tumor part is maintained at an effective treatment level, and compared with drug release particles in other shapes, the drug release particles have the advantages that the killing effect on tumor cells is remarkably enhanced, and the chemotherapy curative effect is improved; through precise process control, the obtained spherical sustained-release particles are regular in morphology and smooth in surface and can be conveniently delivered to a tumor site through an injector, the administration frequency and trauma are reduced, meanwhile, the spherical structure is beneficial to uniform wrapping and slow release of drugs, and toxic reaction caused by sudden increase of local drug concentration is avoided.

This invention discloses a production process and a slow-release potassium polyphosphate fertilizer, belonging to the field of fertilizer technology. The slow-release potassium polyphosphate fertilizer of this invention is obtained by mixing and compressing modified hydrotalcite, composite polylactic acid, potassium polyphosphate, and potassium pentahydrogen bisphosphate into tablets. The modified hydrotalcite is obtained by intercalating hydrotalcite with an amino acid surfactant. The amino acid surfactant is obtained by amidation reaction of sodium amino acids and coconut oil. The composite polylactic acid is obtained by ring-opening polymerization of N,N-dihydroxyethylglycine and lactide. The slow-release potassium polyphosphate fertilizer prepared by this invention has a good slow-release effect and is beneficial to crop growth.

The present invention relates to a method for synthesising a photosensitive polyethylene glycol (PEG) and methyl ether-poly(d,l-lactide) (PDLLA) polymer by tosylating its organic group. The photosensitive PEG-PDLLA polymer is functionalised by opening the Lactide monomer ring by polymerising and covalently bonding with the alcohol terminal group of PEG via an esterification with the tosylated organic group. The nanopolymer obtained using the disclosed method is suitable for controlled release processes of hydrophobic and hydrophilic active ingredients with specific delivery based on photodynamic therapy. The PEG-PDLLA-based nanopolymer obtained is able to encapsulate hydrophobic and hydrophilic active ingredients, configuring a nanocarrier with amphiphilic filler with high potential for photodynamic therapy. The method in turn involves nanoprecipitation by removing the organic solvent with optimal photo response properties to UV light.

The present invention relates to: a liver / adipose tissue dual-targeting composite nano-drug carrier comprising drug-containing poly(L-lactide-co-glycolide) (PLGA) nanoparticles and an adipocyte targeting sequence (ATS) peptide that can target prohibitin; a method for preparing same; and uses thereof for medicines and health foods for preventing or treating obesity or obesity-induced metabolic diseases.

The present invention provides stimulus-responsive gelable liquid composition comprising: vesicles comprising a sterol a cationic quaternary ammonium surfactant, and an active agent; and a stimulus-responsive polymer, wherein: the molar ratio between the sterol and the cationic quaternary ammonium surfactant is from 0.2:1 to 1:1; the sum of the concentration of the sterol and the cationic quaternary ammonium surfactant in the composition is from 1 to 40 mg / ml; and the stimulus-responsive polymer is a polymer selected from the group consisting of a block copolymer comprising at least: a) one block of a polymer selected from the group consisting of polyethylene oxide (PEO) and polyethylene glycol (PEG); and b) one block of a polymer selected from the group consisting of polypropylene glycol (PPG), polypropylene oxide (PPO), polycarbonate (PC), polylactic acid (PLA), poly(lactic-co-glycolic acid (PLGA), poly(3-hydroxybutyrate) (PHB), poly(l-lactide-co-ε-caprolactone) (PLCL), and polycaprolactone (PCL); chitosan and mixtures thereof; and wherein the vesicles comprise at least 50% w / w of the sterol and the cationic quaternary ammonium surfactant of the total weight of the vesicles.

The invention discloses a polylactic resin material for 3D printing and a preparation method thereof, and relates to the technical field of materials. The polylactic resin material for 3D printing prepared by the invention comprises modified polylactic acid and modified silsesquioxane, and the modified polylactic acid is prepared by the following steps: reacting 3-azido-2, 2-bis (azido methyl)-1-propanol with D-L lactide to obtain azido polylactic acid, reacting the azido polylactic acid with tris (4-chloroformylphenyl) phosphine oxide to obtain branched polylactic acid, and reducing to obtain the modified polylactic acid; the modified silsesquioxane is obtained through the steps that octaphenyl silsesquioxane is subjected to sulfonation, acylation and chlorination and then reacts with 1, 2-bis (trimethylsilyl) acetylene to obtain an intermediate, then the intermediate reacts with sodium fluoride, and the modified silsesquioxane with good mechanical performance, flame retardance and self-repairing performance is obtained.

Tissue replacement implants are disclosed that include polarized retinal pigment epithelial cells on a poly(lactic-co-glycolic acid) (PLGA) scaffold, wherein the PLGA scaffold is 20-30 microns in thickness, has a DL-lactide / glycotide ratio of about 1:1, an average pore size of less than about 1 micron, and a fiber diameter of about 150 to about 650 nm. Also disclosed are methods of treating a subject with a retinal degenerative disease, retinal or retinal pigment epithelium dysfunction, retinal degradation, retinal damage, or loss of retinal pigment epithelium. These methods include locally administering to the eye of the subject the tissue replacement implant. In further embodiments, methods are disclosed for producing the tissue replacement implant.

The invention discloses a preparation method of an insect pest prevention chemical fertilizer for vegetables, and relates to the field of chemical fertilizers. Nano silicon dioxide is used as a silicon fertilizer main body, the nano silicon dioxide, sodium bicarbonate and calcium citrate are subjected to spray drying to prepare composite particles, the composite particles are mixed with the self-made pH response insect pest prevention microcapsules and then sprayed to vegetable leaf surfaces, when pests eat the composite particles, acidic substances in oral saliva react with components in the composite particles to enable local pH to be increased, the microcapsules are promoted to be broken, and the insect pest prevention effect is achieved. Terpenoids and jasmonic acid methyl ester are rapidly released, feeding and physiological activities of pests are inhibited, and meanwhile vegetables are induced to start a defense mechanism; the pH response insect pest prevention microcapsule is prepared by taking oxidized paraffin prepared by a biological enzyme catalytic oxidation method as a main wall material, wrapping a core material by adopting an oil-in-water emulsification method, and performing chemical crosslinking on the core material and a polylactic acid-maleic anhydride copolymer, and can quickly release the core material in a weakly alkaline environment and slowly release the core material in a daily process to realize long-acting insect pest prevention. The insect pest prevention chemical fertilizer for vegetables prepared by the invention has an insect pest prevention effect.

The present invention belongs to the field of medicine technology, and specifically relates to the use of poly (L-lactide) and / or a copolymer comprising L-lactic acid repeating units or microspheres thereof, or a composition comprising poly (L-lactide) and / or a copolymer comprising L-lactic acid repeating units or microspheres thereof in the preparation of a drug for preventing and treating obesity and metabolic complications caused by obesity. In an embodiment, the composition further comprises at least one GPR81 agonist. The poly (L-lactide) and / or the copolymer comprising L-lactic acid repeating units, the microspheres thereof, or the composition comprising the same provided by the present invention are capable of preventing the fat and / or body weight of a subject from increasing while maintaining muscle mass, have good effects of reducing weight, increasing muscle mass and regulating glycolipid metabolism, and have no side effects. It can be administered once every few months, which improves patient compliance and provides a new strategy for the treatment of obesity and complications caused by obesity.

The present invention relates to a catalyst for preparing lactide from alkyl lactate and a method for preparing same and, more specifically, to a catalyst for preparing lactide from alkyl lactate and a method for preparing same, the catalyst being capable of preparing lactide, which is used as a monomer of polylactide, from alkyl lactate at a high conversion rate and a high yield.

The application relates to a preparation method of a cyclodextrin / polycaprolactone-polylactic acid polycaprolactone copolymer inclusion complex microsphere, which comprises the following steps: (1) polycaprolactone, lactide and caprolactone are polymerized under the catalysis of stannous octoate to obtain polycaprolactone-polylactic acid polycaprolactone copolymer; (2) the polycaprolactone-polylactic acid polycaprolactone copolymer is preliminarily dissolved in an acetone solution, and cyclodextrin is dissolved in water; (3) the aqueous solution of cyclodextrin is added dropwise into the acetone solution of the polycaprolactone-polylactic acid polycaprolactone copolymer, and stirring is performed intensively; (4) the mixed solution obtained in the step (3) is continuously stirred at room temperature, washed through acetone and water, and dried to obtain an inclusion complex; and (5) the inclusion complex obtained in the step (4) is dispersed in a solvent to obtain an inclusion complex microsphere. The microsphere prepared by the application has biocompatibility, can be dispersed in various solvents, can be used as a carrier of various drugs, and can also be used as a reinforcing filler of polylactic acid.

The invention relates to the technical field of purification and separation of ester organic matters, and discloses a method and a system for refining L-lactide. The method comprises the following steps: (1) carrying out first falling film crystallization on crude lactide to obtain a crystallized material I and a primary mother solution; carrying out first sweating treatment on the crystallized material I to obtain L-lactide and first-grade sweat; (2) performing second falling film crystallization on the first-stage mother liquor to obtain a crystallized material II and second-stage mother liquor; carrying out second sweating treatment on the crystallized material II to obtain L-lactide and second-stage sweat; (3) carrying out third falling film crystallization on the second-stage mother liquor to obtain a crystallized material III and third-stage mother liquor; and (4) carrying out fourth falling film crystallization on the third-stage mother liquor to obtain a crystallized material IV and fourth-stage mother liquor. According to the method provided by the invention, high purity and high yield of lactide can be considered at the same time, and the industrial production requirements of high-molecular-weight polylactic acid are met.

Disclosed herein are scaffolds for osteogenesis comprising a first component and a second component, wherein the first component comprises mineralized collagen glycosaminoglycan (MC-GAG), and the second component comprises poly(D,L-lactide) (PDLLA). Also disclosed herein are methods of promoting osteogenesis and treating bone defects in a subject in need thereof.